tbuckley/cabot-search huggingface dataset:
The influence of atmospheric chromium on selenium content and glutathione peroxidase activity in blood of tannery workers.
Authors: J Gromadzińska, W Wasowicz, M Sklodowska, W Bulikowski, K Rydzyński
Journal: Environmental Health Perspectives (1996)

The concentration of selenium and thiobarbituric acid reactive substances (TBARS) and activity of glutathione peroxidase (GSH-Px) were determined in blood of 34 workers of a tannery in Gniezno, Poland, who worked in an area containing chromium compounds. Fourteen workers were exposed to chromium compounds at concentrations of 0.11 +/- 0.07 mg Cr/m3 (mean +/- SD) and 20 at concentrations 5-10 times lower i.e., 0.022 +/- 0.009 mg Cr/m3. Excretion of Se in urine was measured in all of the investigated workers. Decreased Se concentration in whole blood and blood plasma and elevated TBARS concentration in blood plasma were found in the whole group of investigated tanners as compared to controls. Tanners working in areas with high chromium concentrations had a statistically significant decrease in Se concentration in blood and plasma and decreased urinary excretion of the microelement as compared with other tanners. TBARS concentration was 2.5 times lower in workers exposed to higher chromium concentrations (p < 0.005) than in other workers. Positive linear correlations were found between the concentration of Se in blood and the amount of the element excreted in urine (r = 0.48; p < 0.005), the concentration of Se in blood plasma and in urine (r = 0.46; p < 0.01), and the concentration of Se in blood and erythrocyte GSH-Px activity (r = 0.42; p < 0.02). The observed differences between Se concentration in blood and urine of tannery workers and people who are not employed in the industry may indicate a kind of specific adaptation of the body to the working environment containing chromium compounds.
The Response To Sublingual Immunotherapy With Grass Pollen Extract Administered As A Single Extract Or As Part Of A Multi-Allergen Extract In Patients With Seasonal Allergic Rhinitis Caused By Grass Pollen
Authors: S.M. Amar, R. Harbeck, M. Sills, H. O'Brien, H.S. Nelson
Journal: Journal of Allergy and Clinical Immunology (2009)
TCT-347 Clinical Outcome Of Biolimus-Eluting Versus Sirolimus-Eluting Coronary Stent Implantation In Patients With And Without Diabetes Mellitus: A SORT OUT V Substudy
Authors: Michael Maeng, Evald Christiansen, Hans-Henrik Tilsted, Jan Ravkilde, Per Thayssen, Lisette Jensen, Morten Madsen, Lars Krusell, Hans Erik Bøtker, Leif Thuesen, Jens Flensted Lassen
Journal: Journal of the American College of Cardiology (2012)
Association of asthma symptoms and severity with indoor bioaerosols
Authors: M. A. Ross, L. Curtis, P. A. Scheff, D. O. Hryhorczuk, V. Ramakrishnan, R. A. Wadden, V. W. Persky
Journal: Allergy (2000)

Background : In this study, repeated measurements were made of levels of mold spores, bacteria, and dust‐mite allergens over a 7‐month period in the homes of asthmatics, and relationships with measures of asthma severity were evaluated. Methods : A sample of 57 asthmatic individuals, living in 44 homes in East Moline, Illinois, and nearby communities, participated in a panel study. The homes were visited up to nine times during the study to collect air and dust samples. Asthma severity indicators were derived from questionnaire data and from the daily health records from the panel study. Associations between indoor levels of mold spores, bacteria, and dust‐mite allergens were tested with several asthma severity indicators. Results : There was evidence of associations between all asthma severity measures and levels of total and Gram‐negative bacteria, but mold‐spore abundance was associated only with emergency room (ER) visits for asthma. No significant associations were found with house‐dust‐mite allergen and any of the asthma severity indicators, but the levels of dust‐mite allergen were low, with median concentrations of 0.18 µg/g dust Der f 1 and 0.19 µg/g dust Der p 1. Conclusions : Some evidence was found for associations of increased concentrations of Gram‐negative bacteria and mold spores with asthma severity, particularly with ER visits. No association was found between house‐dust‐mite allergen and asthma severity indicators; however, the mite‐allergen levels in the study homes were generally well below the proposed threshold level of 2 µg/g dust.
TCT-329 Effectiveness of Fluoroscopy-Save versus Cinematography at Reducing Radiation Exposure During Diagnostic Coronary Angiography: A Randomized Controlled Trial
Authors: Binita Shah, Xingchen Mai, Lakshmi Tummala, Chad Kliger, Frederick Feit, Sripal Bangalore, Michael Liou, Michael Attubato, John Coppola, James Slater
Journal: Journal of the American College of Cardiology (2012)
Handbook of Liver Disease
Authors: Daniel R. Ganger
Journal: Annals of Internal Medicine (1998)

Medical Writings1 December 1998Handbook of Liver DiseaseDaniel R. Ganger, MDDaniel R. Ganger, MDRush-Presbyterian-St. Luke's Medical Center, Chicago, IllinoisSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-11_Part_1-199812010-00027 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Handbook of Liver Disease; Friedman LS, Keeffe EB; eds. 510 pages. New York: Churchill Livingstone; 1998. $69.95. ISBN 0443055203. Order phone 800-553-5426.Field of medicine: Hepatology.Format: Softcover book.Audience: Practitioners in primary care, gastroenterology, and hepatology and trainees, including medical students, residents, and fellows.Purpose: To provide rapid access to information on all aspects of liver disease in a concise, practical format.Content: The book is arranged by the major presenting syndromes of liver disease, complications of cirrhosis and liver failure, specific liver pathology, and liver-related issues in systemic conditions or situations.Highlights: All chapters are structured in the ... Author, Article, and Disclosure InformationAffiliations: Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1998Volume 129, Issue 11_Part_1Page: 919KeywordsBiliary systemCirrhosisFood and Drug AdministrationGastroenterology and hepatologyHepatitisLiverLiver diseasesPathogenesis ePublished: 15 August 2000 Issue Published: 1 December 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The Role of Hepatitis C Virus Genotypes in Development of Autoimmune Diseases
Authors: Ayla Sanver, Alper Gurlek, Halis Simsek, Gonca Tatar
Journal: Diabetes Care (2001)

In the study by Betterle et al. (1), it was stated that there was no association between the occurence of organ-specific/nonorgan-specific autoimmune diseases and chronic hepatitis C virus (HCV) infection. It was evident in previous studies (2,3) that there was a clear association among the antigenic subtypes of the HCV, prognosis of disease, autoimmune disease development, and response to …
Foley-catheter induction of labour.
Authors: J R Saunders
Journal: BMJ (1972)

OBJECTIVE: To evaluate whether the polymorphism of Fas promoter -670 is associated with susceptibility to systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and their clinical features. METHODS: A polymerase chain reaction of a genomic DNA-restriction fragment length polymorphism was used to determine genotypes of the Fas promoter -670 in 87 patients with SLE, 87 with RA, and 87 healthy controls. A second cohort of SLE patients (n = 85) was included. Clinical manifestations were analyzed in each patient and correlated with the genotypes. RESULTS: The genotype distribution of the Fas promoter -670 did not differ between patients with SLE and control subjects (AA, GA, GG genotypes 31, 54, 15% vs 30, 55, 15% controls, respectively; chi-squared = 0.03, 2 df, p = 0.99) and between RA patients and controls (AA, GA, GG genotypes 38, 44, 18% vs 30, 55, 15% controls, respectively; chi-squared = 2.30, 2 df, p = 0.32). Regarding the clinical status of lupus patients according to Fas promoter -670 genotypes, there was no significant difference in age at onset, anti-dsDNA titer, C3, C4 level, renal involvement, number of American College of Rheumatology (ACR) criteria met, SLE Disease Activity Index, SLE International Collaborating Clinics/ACR Damage Index, or autoantibody profiles. However, the frequency of anti-RNP antibody was significantly different in the AA, GA, and GG groups (71, 25, 30%; chi-squared = 13.29, 2 df, p = 0.001). To confirm this finding, the Fas promoter -670 genotype was examined in a second cohort of SLE patients (n = 85). The result in the second cohort replicated the association shown in the first. In patients with RA, there was no significant difference in clinical and laboratory findings according to the Fas promoter -670 genotypes. CONCLUSION: Our data suggest that the Fas promoter -670 polymorphism is associated with development of anti-RNP antibodies in SLE.
An Outbreak of Nephritis in Northamptonshire
Authors: M. J. Pleydell, W. J. A. Hall-Turner
Journal: BMJ (1958)

An epidemic of nephritis associated with Streptococcus pyogenes type 12 occurred in York and in predominantly rural areas of the North Riding during the winter months of 1957 and 1958.In several schools in which there was evidence of type 12 infection in 1957 some children were also found with symptomless haematuria.Spread of infection took place in schools and at home.Symp- toms of the initial streptococcal infection were usually present but often slight, and were followed by the onset of nephritis 7 to 24 days later.We are indebted to Dr. R.
DIPEx: fresh insights for medical practice
Authors: A. Herxheimer, S. Ziebland
Journal: Journal of the Royal Society of Medicine (2003)

The Database of Personal Experiences of Health and Illness (DIPEx) launched its website in July 2001. The first two collections (modules) dealt with hypertension and prostate cancer. Now four more modules on other common cancers have been added—breast, bowel, testis and cervix—and work on seven new modules is going on.1 This is a good time to look at what is emerging. The primary aim of DIPEx is to describe the widest practicable range of individual experiences from the patients' points of view and to provide a rich information resource for patients affected by the diseases and for those who look after them. DIPEx inquiries use qualitative methods whereby patients are encouraged to talk without interruption about all aspects of their experiences that mattered to them.
Clinical and molecular correlations in the sickle/β<sup>+</sup>‐thalassemia syndrome
Authors: George F. Atweh, Bernard G. Forget
Journal: American Journal of Hematology (1987)

Abstract Sickle/β thalassemia is a sickling disorder of varying severity which results from compound heterozygosity for sickle cell trait and β‐thalassemia trait. Clinical and genetic studies have shown an inverse correlation between the level of hemoglobin A and the severity of the disease. It has been suggested that the level of hemoglobin A may be a function of the severity of the β‐thalassemia defect. In this study, we use molecular biological techniques to test this hypothesis. We show that the interaction of the mildest of the β + ‐thalassemia genes with the sickle gene results in a high level of hemoglobin A. However, the interaction in this case resulted in a severe sickling disorder in the absence of significant anemia. We hypothesize that a mild β + ‐ thalassemia gene may have two opposite effects on the clinical course of sickle/β + thalassemia: (1) A high level of hemoglobin A which probably confers a favorable antisickling effect and (2) decreased hemolysis leading to increased numbers of total circulating red cells, thereby increasing the blood viscosity and the propensity for sickling. The inheritance of heterozygous α thalassemia 2 in conjunction with the mild β + ‐thalassemia gene and sickle gene in this patient may have further enhanced the latter effect and resulted in a severe sickling disorder.
Dr Hugh Staunton and the Irish Medical Journal
Authors: Hugh Staunton
Journal: JAMA (1989)

<h3>To the Editor. —</h3> The St Patrick's Day feature in<i>JAMA</i>on the<i>Irish Medical Journal</i>has just come to my attention.<sup>1</sup>While I broadly concur with the analysis and sentiments expressed, there are some minor errors of fact relating to my tenure. Since it is very much a "setting the record straight on the<i>Irish Medical Journal</i>," I would like to bring these to the attention of<i>JAMA</i>and its readers. It is stated that, unlike Dr O'Brien, I was a member of the Irish Medical Organization at the time of my application for the post of editor. In fact, I was a member neither at the time of application nor at appointment. I later joined the Irish Medical Association, as it was then called. It is also stated that Dr O'Brien introduced an international peer review system for refereeing scientific articles. In fact, I used such a
Drug hypersensitivity in clonal mast cell disorders: <scp>ENDA</scp>/<scp>EAACI</scp> position paper
Authors: P. Bonadonna, M. Pagani, W. Aberer, M. B. Bilò, K. Brockow, H. Oude Elberink, L. Garvey, H. Mosbech, A. Romano, R. Zanotti, M. J. Torres
Journal: Allergy (2015)

Mastocytosis is a clonal disorder characterized by the proliferation and accumulation of mast cells (MC) in different tissues, with a preferential localization in skin and bone marrow (BM). The excess of MC in mastocytosis as well as the increased releasability of MC may lead to a higher frequency and severity of immediate hypersensitivity reactions. Mastocytosis in adults is associated with a history of anaphylaxis in 22-49%. Fatal anaphylaxis has been described particularly following hymenoptera stings, but also occasionally after the intake of drugs such as nonsteroidal anti-inflammatory drugs, opioids and drugs in the perioperative setting. However, data on the frequency of drug hypersensitivity in mastocytosis and vice versa are scarce and evidence for an association appears to be limited. Nevertheless, clonal MC disorders should be ruled out in cases of severe anaphylaxis: basal serum tryptase determination, physical examination for cutaneous mastocytosis lesions, and clinical characteristics of anaphylactic reaction might be useful for differential diagnosis. In this position paper, the ENDA group performed a literature search on immediate drug hypersensitivity reactions in clonal MC disorders using MEDLINE, EMBASE, and Cochrane Library, reviewed and evaluated the literature in five languages using the GRADE system for quality of evidence and strength of recommendation.
Selective Activation and Expansion of High-Affinity CD4+ T Cells in Resistant Mice upon Infection with Leishmania major
Authors: Laurent Malherbe, Christophe Filippi, Valérie Julia, Gilles Foucras, Monica Moro, Heiner Appel, Kai Wucherpfennig, Jean-Charles Guéry, Nicolas Glaichenhaus
Journal: Immunity (2000)
Abstract A33: Characterization of signaling pathways associated with docetaxel resistance in prostate cancer
Authors: Brian Yong Lee, Falko Hochgrafe, Mark Raftery, Lisa G. Horvath, Roger J. Daly
Journal: Cancer Research (2012)

Abstract Docetaxel (DTX) is the only treatment option for patients diagnosed with metastatic castration-refractory prostate cancer (CRPC). However, approximately 50% of patients do not respond to DTX, but are exposed to significant toxicity without direct benefit. This study aims to use mass spectrometry (MS) based techniques to characterize the perturbed intracellular signaling, particularly tyrosine phosphorylation, which contributes to the chemoresistant phenotype in CRPC patients, and thereby identify novel therapeutic targets. Two DTX-resistant prostate cancer cell lines (DU145-Rx &amp; PC3-Rx) were established from their parental DTX-sensitive cell lines, DU145 &amp; PC3, respectively, by a dose-escalation protocol. Phosphotyrosine profiling was performed by immunoaffinity coupled LC-MS/MS in combination with stable isotope labeling with amino acid in cell culture (SILAC). The chemosensitive and resistant cells were cultured in “light” and “heavy” SILAC media, respectively, and their isotopic labels were switched in a replicate experiment. Phosphotyrosine peptides were analysed on the state-of-the-art High Performance Liquid Chromatography MS/MS (Orbitrap Velos ETD). Raw MS spectra were quantified using MaxQuant software. DU145-Rx &amp; PC3-Rx displayed 44 and 35-fold higher IC50 values, respectively, and significantly greater colony forming ability, in the presence of DTX, compared to the parental lines. Phosphotyrosine profiling of these cell lines identified a total of 365 phosphosites in the chemoresistant lines, corresponding to 227 proteins. 3 kinases and 3 cytoskeletal proteins showed a significant increase in tyrosine phosphorylation in both DTX-resistant models. These candidate proteins will be further characterized by gain- and loss-of-function approaches, both in vitro and in xenograft models, to elucidate the intracellular mechanism of chemoresistance, and to design therapeutic strategies to reverse the chemoresistant phenotype in CRPC. Citation Format: Brian Yong Lee, Falko Hochgrafe, Mark Raftery, Lisa G. Horvath, Roger J. Daly. Characterization of signaling pathways associated with docetaxel resistance in prostate cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Prostate Cancer Research; 2012 Feb 6-9; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(4 Suppl):Abstract nr A33.
Bexarotene (LGD1069, Targretin), a Selective Retinoid X Receptor Agonist, Prevents and Reverses Gemcitabine Resistance in NSCLC Cells by Modulating Gene Amplification
Authors: Patricia Tooker, Wan-Ching Yen, Shi-Chung Ng, Andrès Negro-Vilar, Thomas W. Hermann
Journal: Cancer Research (2007)

Abstract Acquired drug resistance is a major obstacle in cancer therapy. As for many other drugs, this is also the case for gemcitabine, a nucleoside analogue with activity against non–small cell lung cancer (NSCLC). Here, we evaluate the ability of bexarotene to modulate the acquisition and maintenance of gemcitabine resistance in Calu3 NSCLC models. In the prevention model, Calu3 cells treated repeatedly with gemcitabine alone gradually developed resistance. However, with inclusion of bexarotene, the cells remained chemosensitive. RNA analysis showed a strong increase of rrm1 (ribonucleotide reductase M1) expression in the resistant cells (Calu3-GemR), a gene known to be involved in gemcitabine resistance. In addition, the expression of genes surrounding the chromosomal location of rrm1 was increased, suggesting that resistance was due to gene amplification at the chr11 p15.5 locus. Analysis of genomic DNA confirmed that the rrm1 gene copy number was increased over 10-fold. Correspondingly, fluorescence in situ hybridization analysis of metaphase chromosomes showed an intrachromosomal amplification of the rrm1 locus. In the therapeutic model, bexarotene gradually resensitized Calu3-GemR cells to gemcitabine, reaching parental drug sensitivity after 10 treatment cycles. This was associated with a loss in rrm1 amplification. Corresponding with the in vitro data, xenograft tumors generated from the resistant cells did not respond to gemcitabine but were growth inhibited when bexarotene was added to the cytotoxic agent. The data indicate that bexarotene can resensitize gemcitabine-resistant tumor cells by reversing gene amplification. This suggests that bexarotene may have clinical utility in cancers where drug resistance by gene amplification is a major obstacle to successful therapy. [Cancer Res 2007;67(9):4425–33]
Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors
Authors: J.P O'Rourke, H Hiraragi, K Urban, M Patel, J.C Olsen, B.A Bunnell
Journal: Molecular Therapy (2003)

Skeletal muscle is an attractive target tissue for gene therapy involving both muscle and nonmuscle disorders. HIV-1-based vectors transduce mature skeletal muscle; however, the use of these vectors for human gene therapy may be limited by biosafety concerns. In this study, we investigated gene transfer using lentivirus vectors based on the equine infectious anemia virus (EIAV) in skeletal muscle in vitro and in vivo. EIAV vectors transduce proliferating and differentiating C2C12 mouse muscle cells; furthermore, the addition of the woodchuck hepatitis posttranscriptional element to EIAV vectors markedly increases gene expression in these cells. A single injection of EIAV vectors into skeletal muscle of adult mice led to detectable gene marking and gene expression for the duration of the 3-month study. Use of a second-generation EIAV self-inactivating vector (E-SIN) increased transduction in muscle cells in vitro, and injection of E-SIN vectors into skeletal muscle resulted in increased gene marking and gene expression compared to first-generation EIAV vectors.
Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial
Authors: Milton G. Mutchnick, Henry D. Appelman, H. T. Chung, Emma Aragona, Tej P. Gupta, Glen D. Cummings, Jeanne G. Waggoner, Jay H. Hoofnagle, David A. Shafritz
Journal: Hepatology (1991)

Chronic hepatitis B is a severe and frequently progressive disease. We assessed the safety and efficacy of thymosin fraction 5 and thymosin-alpha 1 in a prospective, placebo-controlled trial in 12 patients with chronic hepatitis B. All patients had histological and biochemical evidence of active liver disease for at least 6 mo before treatment and were positive for serum hepatitis B virus DNA and HBsAg. Seven patients received thymosin fraction 5 or thymosin-alpha 1 and five patients received placebo twice weekly for 6 mo. By the conclusion of the study (1 yr), serum aminotransferase levels had improved significantly in thymosin-treated patients, but not in the placebo group. Six (86%) of the thymosin treated patients and one (20%) patient given placebo cleared hepatitis B virus DNA from serum (p less than 0.04, Fisher's exact test). After treatment, replicative forms of hepatitis B virus DNA were present in the liver specimens of four of five placebo-treated patients but in only one of seven thymosin-treated patients (p less than 0.04, Fisher's exact test). Response to thymosin therapy was associated with significant improvements in peripheral blood lymphocyte and CD3 and CD4 counts and in in vitro production of interferon-gamma over initial values. No significant side effects were observed in patients given thymosin or in placebo-treated patients. Clinical, biochemical and serological improvement in patients responding to thymosin were sustained during 26 +/- 3 mo of follow-up. The results of this pilot trial suggest that thymosin therapy promotes disease remission and cessation of hepatitis B virus replication in patients with chronic viral infection.